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Abstract
Purpose To learn from patient safety
incidents (PSIs) following recent introduction
of vascular endothelial growth factor inhibitor
medications (anti-VEGF) in ophthalmic care,
as reported via a national incident reporting
database.
Methods Thematic retrospective review of
anti-VEGF medications PSIs as reported via
clinical incident reporting methods in NHS
care in England and Wales from 2003 to 2010,
ascertained from database mining at the
National Patient Safety Agency (NPSA).
Results In all, 166 relevant anti-VEGF
incidents were reported. Reports have
increased year on year from 2006. Incident
severity as reported: 10 were reported as
‘severe harm’ and 23 as ‘moderate harm’.
The remainder were ‘low’ or ‘no harm’ events.
The incident themes and/or causes found and
by order of severity included: intra-ocular
inﬂammation/endophthalmitis (n¼16);
treatment or follow-up delays (n¼45); wrong
medication (n¼26); wrong eye/patient
injection (n¼17); missing records (n¼12).
Other problems included medication
availability and refrigeration failures. We
reﬂect on potential solutions for addressing
the matters found. Systemic safety matters,
stroke, subdural hemorrhage, and myocardial
infarction (total n¼3) followed anti-VEGF
treatments.
Conclusion Although infrequent, anti-VEGF
medication PSIs or errors do occur and are
thus a threat to quality. This review also
provides supporting evidence to existing
concerns and challenges surrounding
age-related macular degeneration service
pressures and provision. Lessons for
improvement of care from a national incident
reporting database for a frequently
undertaken and recently introduced
ophthalmic procedure were found.
Suggestions are proposed for improving
quality by reducing such problems based on
analysis of such reports. Endophthalmitis
reports following intra-vitreal injections
suggest rigorous infection control measures
are required.
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Introduction
Age-related macular degeneration (AMD) is the
leading cause of blindness in developed
economies. Neovascular or wet-AMD accounts
for more than half of all cases of registered sight
and severe sight impairment, and
approximately 26000 new cases of wet-AMD
develop every year in the UK.
1,2 There have
been major recent advances in the treatment of
wet-AMD with the use of biological agents and
in particular with vascular endothelial growth
factor (VEGF) inhibitor medicationsF
frequently termed ‘anti-VEGF agents’F
following publication of key trial results.
3–5
These studies showed that wet-AMD patients
treated with frequent (monthly or 6 weekly)
intra-vitreal injections of anti-VEGF agents had
a greatly reduced risk of visual loss compared
with no treatment or other existing treatments.
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YInterim guidelines on the use of anti-VEGF agents based
on these key trials were published in 2006.
6 The Royal
College of Ophthalmologists (the College) provided
guidance on provision of AMD services in 2007.
7 By
August 2008, the National Institute for Health and
Clinical Excellence (NICE) advised the NHS that such
treatment with the anti-VEGF agent ranibizumab
(Lucentis; Novartis (Basle, Switzerland) and Genentech
(San Francisco, CA, USA) was cost effective.
8 At the same
time, guidance from the College clariﬁed treatment
recommendations.
9 Thus commissioners of NHS care
that is primary care trusts in England and local health
boards in Wales have had a duty to commission such care
for AMD patients from late 2008, and NHS hospitals
have had a duty to comply with the NICE treatment
guidelines. As wet-AMD is a common condition and as
treatment requirements are frequent, this innovation has
consequently required ophthalmic departments to cope
with a signiﬁcant volume of new activity. In a survey of
ophthalmology departments undertaken in 2009, the
College found there are considerable issues with the
provision of anti-VEGF injection therapy in the NHS.
10
The potential for sub-optimal clinical outcomes is real.
Signiﬁcant vision can be lost in a short time if wet AMD
is not treated,
11 and this can have a huge impact on
independence and quality of life for patients.
12
Following several inﬂuential reports on patient safety,
learning from clinical failure or incident is now widely
regarded as a core principle underpinning improvement
in patient safety.
13 The National Patient Safety Agency
(NPSA) (http://www.npsa.nhs.uk) was thus initiated.
A patient safety incident (PSI) is considered by the NPSA
as an unintended or unexpected incident, which could
have or did lead to harm for one or more patients. This is
also referred to as an adverse event/incident or clinical
error and includes ‘near misses’. The NPSA includes a
system for logging and gathering patient safety incidents
(PSIs) at national level following local reporting. NHS
organizations in England and Wales now forward local
PSI reports to a national reporting and learning system
(NRLS) repository database at the NPSA. Direct
reporting to the NRLS is also possible.
14 Following a
Department of Health review in July 2010, the NPSAwill
be abolished and it is proposed that some of its functions
will be transferred to a Patient Safety subcommittee of
the new NHS Commissioning Board.
15
Following the NICE guidance on wet-AMD treatment in
2008 and in the light of the College’s concerns in 2009 about
development of and provision of services for patients in the
modern anti-VEGF era, we reviewed PSI reports on the
NRLS database at the NPSA. We sought to identify reported
incidents in anti-VEGF treatments in ophthalmic care. We
aspired to identify any themes in these reports and to
propose, if possible, measures to improve care.
Patients and methods
NHS providers in England and Wales report PSIs to the
NPSA using local electronic submission processes. The
information reported includes; clinical specialty, staff
involved, location and time of the incident, degree of
patient harm, and free text description of the incident. All
submitted PSI reports are made anonymous within the
NRLS database. Access to review an NRLS search was
granted to one of the authors (SPK). The intention of this
project was to identify incidents related to anti-VEGF
treatments.
A search of the NRLS database by keyword was
undertaken in June 2010. All anti-VEGF-related incidents
reported from 2003 to the database up to and including
June 2010 were included. First, the free text ﬁelds were
searched for instances of any of the terms: ranibizumab,
Lucentis; bevacizumab (Avastin, Roche (Basle,
Switzerland) and Genentech) pegaptanib (Macugen,
Pﬁzer, New York, NY, USA) and ‘injection’ and/or
ophthalmology as area of care. Spelling mistakes or wild
cards of these words were also considered.
All incident reports so retrieved from the NRLS
database were reviewed. Thematic analysis of such cases
as reported was undertaken. Our analysis was based on
the narrative details provided in such reports only.
Results
The NRLS database held circa 5.5 million incident reports
on the 16 June 2010, of which 26740 records were
reported as related to the specialty of ophthalmology. Of
these PSI reports, 166 cases/incidents were found
relevant and where an anti-VEGF ophthalmic medication
agent was mentioned in the report. The study period was
from the initial roll out of the NRLS system throughout
2003 and until 16 June 2010. Analysis of the 166 PSIs was
undertaken with a view to identify the themes or sources
of potential error. Table 1 provides the principal reasons
by theme for the anti-VEGF PSI reports. Multiple causal
factors were not reported or speciﬁcally identiﬁable on
any incident reports. Broadly speaking, where a theme
was discernable, safety issues included: infection and
inﬂammation problems; delay in referral, treatment or
follow-up; medication availability and mix-ups;
problems matching correct patient and to laterality. In
our opinion, several of these matters reported revealed
themes, which may have preventable measures. Table 2
provides examples of PSI reports. The text of the PSI
report and grade of incident severity provided are as
reported. Table 3 provides incidents reported by
anti-VEGF medication agent and year. Our suggestions
for possible measures for prevention or mitigation are
presented in Table 4.
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No factors related to type of staff present (ie, rotating or
locum or permanent staff) were discernable from the PSI
reports. In all, 10 PSIs were graded by the reporters as
‘severe’ and 23 as ‘moderate’ harm. A total of 111 were
graded ‘low’ or ‘no’ harm. There were no ‘near miss’
incidents reported. No deaths were reported. Incident
dates: 4 reports were in 2006; 11 in 2007; 40 in 2008; 75 in
2009, and 36 in 2010 (up to middle of June 2010). Of the
16 cases of endophthalmitis/severe inﬂammation
reported, 2 were associated with bevacizumab injection
and 14 with ranibizumab injection. There were no
anti-VEGF reports in ophthalmic care in 2003–2005, and
these agents were not then available to ophthalmologists.
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Table 2 Free text reports; examples from selected PSI reports by theme
Incident theme Incident text as reported Incident severity as
reported
Endophthalmitis K Patient admitted following Avastin injection (date stated) to operating theatre
for right vitreous tap with antibioticsFrepeated on (another date stated) and
may need further surgery.
Severe
Wrong injection K Patient seen by consultant in clinical room after visual acuity had been
checked. Patient was due for second Lucentis injection. Consultant then saw 3
more patients. Patient then taken into AMD room for procedure and
consented by consultant. Prepared for procedure and injected left eye. Health
care assistant came in and pointed out wrong eye but already injected. Patient
escorted to waiting area.
Low
K 0.5ml intravitreal lidocaine given in error, thinking it was the Lucentis




K The pharmacy has only one available Lucentis injection for 2 cases.
Apparently the ordered drug has not come in time for case this morning
hence we have to cancel one patient.
Moderate
K Drug fridge was off all weekend and noted at 11:30 to be at 20C. The fridge
temperature is checked daily and was in working order on the previous
Friday. 2 syringes of ranibizumab had been issued on Monday morning
before the fridge temperature had been discovered. 2 patients were given the
injection.
No harm
Error in follow up K Patient having 3 initial injections of Lucentis, put down for review one month
after the 3rd but was not given appointment till nearly 3 months after this. He
needed monthly treatment but his follow up was not on time due to busy
clinics.
Moderate
K 40Patients identiﬁed who had received intravitreal ranibizumab therapy
earlier than the recommended 28 day interval since (date stated). Patients
were identiﬁed retrospectively and to date there has been no adverse medical
outcome.
None
K Patient attended AMD services on (date stated). Diagnosis bilateral AMD.
Plan of treatment right and left Lucentis intra vitreal injection. Left eye to be
treated ﬁrst. At this stage left eye was treatable. Patient put on waiting list
next available date being 26 days following. On this day left eye visual
activity reduced to 8 letters only therefore too much vision lost and treatment
no longer viable. Only treatment could be given to the right eye.
Severe
Reports are largely in the unedited words of reporters. Any identiﬁable dates or place names have been removed.
Table 3 Anti-VEGF medication incidents reported by year
Year Ranibizumab Bevacizumab Pegaptanib
2006 3 1 0
2007 6 5 0
2008 29 11 0
2009 58 16 1
2010
a 29 7 0
Total 125 40 1
aNote: 6-months data only for 2010.
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The NRLS database contained close to 27000 PSI reports
related to ophthalmology care from England and Wales
by the middle of June 2010.
The data show instances of the wrong patients and
wrong eyes receiving intra-vitreal anti-VEGF injections.
Medical and surgical confusions (ie, wrong patient,
wrong medication, wrong site or side surgery, wrong
procedure, or implant) are an infrequent but long
recognized and important and preventable cause of
patient morbidity and complaint in general, and relevant
to ophthalmic surgeons.
16,17
Under-reporting of PSIs is widespread and recent
studies found that only a minority of NHS incidents are
reported.
18 Medical staff have barriers to incident
reporting and reporting is often nurse-led.
19–21 Thus, this
review almost certainly underestimates the number of
anti-VEGF incidents occurring in NHS care during the
study period, although it is likely to be indicative of the
types of adverse event and near miss which may occur. A
weakness of our retrospective review from a data set is
that clinical detail of the cases on the data set is scant,
and root causation of misadventures is not provided
within reports. PSI causation is not described by
reporters in a standard format, or at all. Rather PSI
reports are provided in free text by the reporter and
frequently contain anecdote-based opinion. Furthermore,
the severity of patient harm is self-declared by the PSI
reporter. The NPSA’s guidance ‘7 Steps to Patient Safety’
provides a framework for incident reporting and it
includes a classiﬁcation of severity grading.
22 We cannot
tell if this was adhered to. There were cases where
patients suffered injections into the wrong eye, but the
degree of harm from the original PSI was labeled as ‘no
harm’. Another potential weakness of the present review
is that adverse drug reactions (ADRs) in the UK are
reported to the Medicines and Healthcare products
Regulatory Agency (MHRA) through the Yellow Card
Scheme (http://www.yellowcard.gov.uk) rather than via
patient safety reports. Thus our study does not capture
any ADR that may have been reported via that
mechanism or indeed directly to medication
manufacturers or license holders. Nevertheless, this
review demonstrates that it is also possible in part to
track or monitor patient safety issues arising from a new
treatment/procedure introduced into care from about
2006 onwards. Using similar methods of analysis of the
NRLS has been undertaken to explore safety reports of
certain anesthetic agents.
23
Broadly speaking, safety issues we found included:
infection and inﬂammation problems; delays in
treatments; medication availability and mix-ups;
problems matching correct patient/eye, and laterality.
Many of these are a reﬂection of the challenges of clinical
care such as avoiding healthcare-associated infections
and matching correct medications, and data to correct
patients. We found similar problems of confusion in
ophthalmic care in a review of intra-ocular lens implant
incidents reported via the NRLS.
24 Mix-ups causing harm
when medications are injected into the wrong part of the
eye are a microcosm of medication errors. The
inadvertent intra-vitreal injection of cefuroxime
Fperhaps intended for sub-conjunctival injectionF
instead of ranibizumab (Lucentis) intended for intra-
vitreal injection was reported and led to retinal toxicity
and visual loss. Likewise, inadvertent intra-vitreal
injection of lidocaine Fintended for ocular surface
anesthesiaF instead of ranibizumab (Lucentis) intended
for intra-vitreal injection in another two incidents were
reported.
This review cannot propose solutions to all the service
delivery issues of the introduction of novel treatments.
Much service development work is underway on
attempting to improve services for wet-AMD patients by
the College, patient support groups, and the National
Eye Care Plan. However, certain signals emerge from this
review and from which some lessons can be learned.
Firstly, the widespread recent introduction of intra-
vitreal injections has created a new potential source of
healthcare acquired endophthalmitis and intra-ocular
inﬂammation. The reported incidence of endophthalmitis
per injection in various studies ranged from 0.02
to 1.9%
3–5,25–29 Several of the cases of infection/
endophthalmitis in such publications were attributed to
protocol violations, chief of which was not using an eye
lid speculum at the time of injection.
25 With better
attention to aseptic technique later in the early key
clinical trials, the incidence of post-injection
inﬂammation and infection decreased. A recent meta-
analysis of the US literature from 2005 to 2009 reported
52 cases of endophthalmitis after 105536 intra-vitreal
Table 4 Authors’ suggestions for reducing anti-VEGF incidents
K Providers and commissioners of wet-AMD clinical services
should plan services based on realistic estimates of
wet-AMD incidence.
K Follow best evidence in anti-VEGF medication care.
K Maintain high standard of aseptic technique for intra-vitreal
injections.
K Consider electronic patient records, electronic prescriptions,
and audit tools.
K Consider pre-injection checklist and ‘time out’, especially for
high volume and/or mixed surgical schedules/lists.
K Ensure adequate stock of anti-VEGF medication is in place
in injection facility.
K Alarmed refrigerators for anti-VEGF agent storage and
reliable medication supply services are vital.
Anti-VEGF patient safety incidents
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30 Injection room facilities
have been developed for intra-vitreal injection at
ophthalmic facilities in the UK. We understand
informally from peer discussions that the cases of
infectious intra-ocular inﬂammation/endophthalmitis in
NHS care in 2009, may have been due to breaches in
asepsis techniques or infrastructure in injection room
facilities in two centres. We understand informally that
following changes of practise that such episodes have
reduced/stopped at those facilities (Discussion at
Medical Retina Group Annual Meeting, Oxford, 2010).
Intra-vitreal injections are an invasive procedure and are
not risk free, and must be taken seriously by all
concerned. We stress that eye-care teams undertaking
intra-vitreal injections need to be vigilant concerning
aseptic technique. The requirement for frequent
injections makes this cumulative risk of intra-ocular
infection relevant to individual patients. Results of the
British Ophthalmic Surveillance Unit (BOSU) study of
endophthalmitis cases over the same time period
following anti-VEGF injections are awaited with
interest.
31
Second, on a service provision level the frequency of
anti-VEGF injections or assessments required, to achieve
good clinical outcomes in wet-AMD, requires a
commitment to commission a service with adequate
clinical manpower/infrastructure. It is necessary in our
opinion, based on the key clinical trials to ensure that the
frequent intra-vitreal injections or clinic assessments
required are provided safely and in a timely fashion
(usually monthly), in order to provide continuing
protection against visual loss. The present patient safety
incident reports, highlight capacity has been problematic
at times in hospital eye services in England and Wales.
This mirrors the concerns of the College’s audit on
provision of such services in the UK in 2009.
10 We
suggest that commissioners and providers agree
appropriate service level agreements to ensure that AMD
patients receive the appropriate care and in compliance
with the relevant NICE guidance. Support from both
hospital management and commissioners is needed to
ensure such arrangements. Monitoring of patient clinical
outcomes is also of merit to ascertain if satisfactory
outcomes are being achieved, in what is a challenging
new pressure on ophthalmology departments.
Third, many errors with anti-VEGF treatments
reported were not complex technological matters or
organizational issues. Many problems occurred due to
missing clinical records, prescription mix-ups, and
communication breakdowns. Again these are a mirror of
organizational patient safety challenges.
Fourth, it is important in our experience to maintain a
smooth ﬂow during treatment sessions and to keep
distractions or interruptions at the lowest possible level.
The Patient Safety First campaign
32 and many similar
initiatives recommend both a team brief before surgery
and taking ‘time out’ and a checklist before starting the
surgical procedure. The ever-present risk of wrong
patient or wrong eye errors in the high-throughput
environment of a wet-AMD injection service requires
constant vigilance.
Fifth, PSI reports of lack of medication availability and
refrigeration failures reﬂect the relatively high costs of
anti-VEGF medications, and the need to order these
agents and store them in a refrigerator at a temperature
of 2–81C. In our opinion, this high medication cost may
have stimulated reporting by staff whenever supply
problems or waste of such medications occurred. The use
of refrigerators with temperature alarms and logs is of
merit in the storage of anti-VEGF medication agents.
Reliable supply chains for medication delivery to
providers at the correct temperature are critical. We have
thus suggested that assistance Fincluding replacement
of wasted medicationsF from the pharmaceutical
suppliers or manufactures to hospital pharmacies be
improved upon and await developments.
In relation to systemic safety matters, few reports
located were relevant. One report of stroke, other of
subdural haemorrhage, and another of possible
myocardial infarction following intra-vitreal treatments
occurred. Although these are potential side effects of
VEGF inhibitor, their proximity to treatment does not
necessarily indicate causality. No deaths were reported.
Patient safety incident reporting is not an appropriate
tool to undertake pharmacovigilance surveillance.
Pharmacovigilance is deﬁned by the World Health
Organisation as ‘the science and activities relating to the
detection, assessment, understanding and prevention of
adverse effects or any other drug-related problem’.
33 This
is topical in patient care as bevacizumab is not approved
for intra-vitreal injection, but is often so used.
34 The
present review does not add any additional speciﬁc
pharmacovigilance signals to those already known in
relation to the safety proﬁle of any of the intra-vitreal
anti-VEGF medication treatments, approved or
un-licensed. Systemic safety signals may perhaps be
detectable from healthcare resource usage databases and
as signaled in the recent review of Medicare claims
following treatment of AMD.
35 In the UK suspected
adverse drug reactions (ADR), both systemic and ocular,
should be reported to the Medicines and Healthcare
products Regulatory Agency (MHRA). ADRs should be
reported for both licensed and unlicensed indications, to
allow effective monitoring of the safety of medicines in
real-life practice. It would be of interest to triangulate our
ﬁndings with ADR reports on the MHRA’s databases.
Spontaneous ADR reporting is also thought be an
underestimate of ADR events.
36 It should also be
Anti-VEGF patient safety incidents
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monitoring, detection, and assessment of ADRs and that
spreading good practise, service improvement, and
learning from safety reports is important to improving
clinical outcomes.
Moving forwards, as anti-VEGF agents also improve
clinical outcomes in other retinal patients, such as those
affected by diabetic macular edema (DMO)
37 or retinal
venous occlusions (RVO),
38 these further treatment
developments and emerging guidelines
39 are likely to
put further pressures on retinal services and intra-vitreal
injection services. Lessons from anti-VEGF use during
the roll out phase of such medications in AMD care in
England and Wales may assist the extra challenges for
DMO and RVO patient management now on the horizon.
In conclusion, this retrospective review of PSIs as
reported to a national database demonstrates that
learning from such a database has some merit in
supporting provision of anti-VEGF medication care in
ophthalmology. We encourage ophthalmic teams to
undertake more patient safety reporting, both PSI
reporting and ADR reporting, in the present anti-VEGF
era. The Royal College of Ophthalmologists has provided
guidance on patient safety for ophthalmic teams.
40
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